NLM Digital Collections

Search

Start Over Subjects Buprenorphine -- therapeutic use ✖Remove constraint Subjects: Buprenorphine -- therapeutic use Subjects Opiate Substitution Treatment ✖Remove constraint Subjects: Opiate Substitution Treatment Copyright Copyright may apply ✖Remove constraint Copyright: Copyright may apply

1. The role of community health centers in addressing the opioid epidemic

Author(s):
Zur, Julia, author
Tolbert, Jennifer, author
Sharac, Jessica, author
Markus, Anne, author
Publication:
San Francisco, CA : Henry J. Kaiser Family Foundation, July 2018
Subject(s):
Community Health Centers -- statistics & numerical data
Opioid-Related Disorders -- drug therapy
Opioid-Related Disorders -- prevention & control
Buprenorphine -- therapeutic use
Drug Overdose -- epidemiology
Inservice Training
Medicaid
Methadone -- therapeutic use
Naloxone -- therapeutic use
Naltrexone -- therapeutic use
Opiate Substitution Treatment
Practice Patterns, Physicians'
Prescription Drug Misuse -- statistics & numerical data
State Government
Humans
United States

2. Extended-release opioid agonists and antagonist medications for addiction treatment (MAT) in patients with opioid use disorder: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, December 3, 2018
Subject(s):
Analgesics, Opioid -- therapeutic use
Narcotic Antagonists -- therapeutic use
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Buprenorphine -- therapeutic use
Buprenorphine, Naloxone Drug Combination -- therapeutic use
Cost-Benefit Analysis
Methadone -- therapeutic use
Naltrexone -- therapeutic use
Treatment Outcome
Humans
United States

3. Why health plans should go to the "MAT" in the fight against opioid addiction

Author(s):
Elitzer, Julia, author
Tatar, Margaret, author
Publication:
[Oakland, Calif.] : California Health Care Foundation, September 2017
Subject(s):
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Opioid-Related Disorders -- prevention & control
Buprenorphine -- therapeutic use
Comparative Effectiveness Research
Cost Savings
Drug Overdose -- drug therapy
Drug Overdose -- prevention & control
Health Care Costs
Health Services Accessibility
Healthcare Disparities
Inappropriate Prescribing -- prevention & control
Insurance Coverage -- legislation & jurisprudence
Managed Care Programs
Medicaid
Mental Health Services -- legislation & jurisprudence
Methadone -- therapeutic use
Naloxone
Naltrexone -- therapeutic use
Neonatal Abstinence Syndrome -- drug therapy
Opioid-Related Disorders -- epidemiology
Patient Care Management
Prescription Drug Diversion
State Government
Humans
California
United States

4. Substance use in California: a look at addiction and treatment

Author(s):
Holt, Wendy, author
Publication:
Oakland, CA : California Health Care Foundation, October 2018
Subject(s):
Substance-Related Disorders -- epidemiology
Substance-Related Disorders -- therapy
Adult
Adolescent
African Americans
Alcohol-Related Disorders -- epidemiology
Alcohol-Related Disorders -- mortality
Asian Americans
Buprenorphine -- therapeutic use
Comorbidity
Counseling -- education
Emergency Medical Services
Emergency Service, Hospital
European Continental Ancestry Group
Facilities and Services Utilization
Financing, Government
Hispanic Americans
Hospital Bed Capacity
Marijuana Abuse
Medicaid
Mental Disorders
Oceanic Ancestry Group
Opiate Substitution Treatment
Opioid-Related Disorders
Pregnancy
Prescription Drug Misuse
Prisoners
Sexual and Gender Minorities
State Government
Substance Abuse Treatment Centers -- statistics & numerical data
Substance-Related Disorders -- drug therapy
Substance-Related Disorders -- economics
Substance-Related Disorders -- mortality
Young Adult
Humans
California
United States

5. Increasing access to medications for opioid use disorder: policy strategies during and after COVID-19 pandemic

Author(s):
Au-Yeung, Caroline M., author
Blewett, Lynn A., author
Winkelman, Tyler N.A., author
Publication:
New York, NY : Milbank Memorial Fund, October 2021
Subject(s):
Health Services Accessibility
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Buprenorphine -- therapeutic use
COVID-19
Health Policy
Methadone -- therapeutic use
Naltrexone -- therapeutic use
United States

6. MAT in the emergency department: FAQ

Author(s):
Newman, Sandra, author
Publication:
[Oakland, California] : California Health Care Foundation, March 2019
Subject(s):
Emergency Medical Services
Emergency Service, Hospital
Insurance, Health, Reimbursement
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Substance-Related Disorders -- drug therapy
Buprenorphine -- therapeutic use
Inservice Training
Methadone -- therapeutic use
State Government
Telemedicine
Humans
California
United States

7. MAT for hospitalized patients

Author(s):
Newman, Sandra, author
Publication:
[Oakland, California] : California Health Care Foundation, June 2019
Subject(s):
Hospitalization
Inpatients
Insurance, Health, Reimbursement
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Buprenorphine -- therapeutic use
Drug Costs
Hospital Costs
Methadone -- therapeutic use
Reimbursement Mechanisms
State Government
Humans
California
United States

9. Buprenorphine: an overview for clinicians

Author(s):
Steiger, Scott, author
DeFries, Triveni, author
Publication:
[Oakland, California] : California Health Care Foundation, August 2019
Subject(s):
Buprenorphine -- therapeutic use
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Ambulatory Care
Buprenorphine -- administration & dosage
Buprenorphine -- adverse effects
Drug and Narcotic Control
Emergency Service, Hospital
Health Services Accessibility
Mental Health Services
Methadone -- therapeutic use
Naltrexone -- therapeutic use
Pain -- drug therapy
Prescription Drug Diversion
Prisons
State Government
Telemedicine
Humans
California
United States